Replimune's First Commercial Readout Will Reveal Whether the Launch Survived Its Own Hype

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Replimune typically reports before the market opens, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price behavior shows moderate volatility around earnings releases, with an average absolute Day 0 move of 3.20% and Day +1 move of 3.34%. Intraday ranges have been wider, averaging 9.01% on Day 0 and 8.88% on Day +1, indicating significant intraday swings even when closing moves are more contained.

The directional pattern has been mixed but slightly negative, with five of the past eight releases resulting in Day 0 declines. The most volatile reaction came in May 2025, when the stock surged 3.55% on Day 0 with a 19.35% intraday range, followed by a 4.68% decline on Day +1. More recently, the August 2026 release produced a muted 1.45% Day 0 decline with a 4.64% range, suggesting the market had largely priced in expectations. Given this quarter's significance as the first commercial revenue report, investors should anticipate volatility closer to the historical average range of 9%, with the potential for larger moves if initial TUDRIQEV sales materially exceed or fall short of expectations.

Part 2.2: Options Market Expected Move

The options market is pricing a 9.70% expected move through October 30, 2026, slightly above the historical average Day 0 move of 3.20% but in line with the average intraday range of 9.01%. This suggests options traders are anticipating elevated volatility consistent with the significance of this first commercial revenue report, though not dramatically above historical norms.

Part 3: What Analysts Are Saying

Wall Street maintains a bullish consensus on Replimune, with an average rating of 4.33 out of 5.0 (between Buy and Strong Buy). The analyst community is heavily skewed positive, with 7 Strong Buys, 0 Moderate Buys, 1 Hold, 0 Moderate Sells, and 1 Strong Sell among the 9 analysts covering the stock. The mean price target of $19.50 implies 49.4% upside from the current price of $13.05, with a range spanning $14.00 to $24.00.

Analyst sentiment has remained unchanged over the past month, reflecting stable conviction in the commercial opportunity despite the uncertainty around early launch metrics. The wide target range—from $14.00 to $24.00—underscores the divergence in views on TUDRIQEV's revenue potential and the timeline to profitability. The single Strong Sell rating appears to be an outlier, with the overwhelming majority of analysts expressing confidence in the company's long-term prospects.

Looking ahead, analysts project significant revenue growth, with fiscal 2028 consensus revenue of $172.6 million representing a 497.81% increase from fiscal 2027 estimates of $28.9 million. EPS estimates show a path toward narrowing losses, with fiscal 2028 consensus at $2.04 per share compared to $2.82 for fiscal 2027, a 27.66% improvement. This optimistic outlook reflects expectations that TUDRIQEV will gain meaningful market share in the advanced melanoma setting and that operating leverage will emerge as revenue scales.

Part 4: Technical Picture

Replimune enters earnings with a Buy signal at 56%, unchanged from one month ago but significantly stronger than the 24% Buy signal registered one week ago, indicating recent technical improvement. The stock is trading at $13.05, positioned above its 5-day ($12.14), 10-day ($11.72), 20-day ($12.41), 100-day ($12.12), and 200-day ($9.17) moving averages, but below its 50-day moving average at $13.45. This configuration suggests near-term momentum is positive, though the stock faces resistance at the 50-day level.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is constructive but not overwhelming, reflecting recent gains tempered by proximity to resistance
• Medium-term (50% Buy): Moderate buy signal suggests consolidation in the intermediate timeframe, with the stock digesting recent advances
• Long-term (100% Buy): Strong buy signal reflects robust longer-term uptrend, with the stock trading well above its 200-day moving average

Trend Characteristics: The Average strength and Average direction suggest a balanced technical environment heading into earnings, with neither extreme bullish momentum nor bearish pressure dominating the setup.

The 50-day moving average at $13.45 represents the key near-term resistance level, just 3.1% above the current price. A strong earnings reaction could propel the stock through this technical ceiling and open the door to a test of the $14.00 level. Conversely, disappointment could send shares back toward support at the 20-day moving average of $12.41. The overall technical setup is cautiously supportive, with the stock holding above most key moving averages and showing improving momentum, but the proximity to resistance and the 9.70% expected move suggest investors should brace for significant volatility. The long-term uptrend remains intact, providing a constructive backdrop for bulls, but the near-term setup offers limited cushion if results disappoint.